Symphogen - Gilde Healthcare



Copenhagen, Denmark

Polyclonal Antibody Therapeutics
Since: 2007

Symphogen is a leader in the development of antibody mixtures to improve the treatment of cancer.

Symphogen’s technology is uniquely suited for targeting multiple molecules, which is key to dealing with complex diseases such as cancer.

The Danish company, based in Copenhagen, generates revenues from out-licensing drug candidates to large pharmaceutical companies. Its pipeline addresses large commercial markets (> $1 billion) in oncology.

Since Gilde invested in Symphogen, the company has expanded and advanced its product pipeline, and strengthened and broadened its technology platform. Its lead oncology product was out-licensed to Merck in 2012 following a positive phase-2 trial in late-stage cancer patients. Symphogen also initiated commercial agreements with Genentech.

More Symphogen news

Symphogen presents detailed results for randomized Phase 2 study with Sym004 in refractory metastatic colorectal cancer at ESMO 2017 Congress

Symphogen Initiates Anti-MET Clinical Program

Baxalta and Symphogen Establish Strategic Collaboration to Accelerate Innovation in Immuno-Oncology

Symphogen Announces Closing of a EUR 67.5 M Financing Subscribed by Existing Investors

Symphogen Regains Rights to Sym004 / Announces Organizational Changes

Sym004 Advances into Two New Clinical Trials and Receives Milestone Payments

Symphogen Relocates to New Headquarters, Names Chief Manufacturing Officer

Symphogen Enters Clinical cGMP Manufacturing Agreement with Gallus

Symphogen Receives Milestone Payment in Merck KGaA Sym004 Collaboration

Symphogen Reports New Data on Anti-EGFR Monoclonal Antibody Mixture

Symphogen Expands Previous Private Equity Round, Reaching a Total of €141 million (USD 185 million)

Symphogen Presents New pan-HER data at Annual AACR Meeting

Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck

Symphogen Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at ASH

Symphogen Presents Preliminary Results from Phase 2 Clinical Trial with Rozrolimupab

Symphogen names new Chief Scientific/Medical and Business Officers Senior Management Team Complete

Symphogen Raises EUR 100 Million, The Largest Private Round In European Biotech Ever

Symphogen Receives Milestone Payment from Genentech for Antibody

Symphogen and Swedish Orphan Biovitrum receive U.S. orphan drug designation for Rozrolimupab in ITP

SYMPHOGEN Issued United States Patent Covering Symplex Technology for Antibody Discovery

SYMPHOGEN – Sympress II Production System Enables Antibody Manufacturing

SYMPHOGEN Announces Initiation of Phase 1/2 Trial of Sym004 in Patients with Advanced Solid Tumors

Symphogen Publishes Pre-Clinical Data in Cancer Research Demonstrating Superior Efficacy

Symphogen Opens US Operations in Princeton, New Jersey

Symphogen Appoints Adriann Sax Chief Business Officer

SYMPHOGEN and Origen Collaborate to Produce Transgenic Chicken for generation

SYMPHOGEN Secures EUR 33 million Financing to Support Clinical Development of Antibody Products

YMPHOGEN Adds Receptor’s Pan-HER Ligand Trap Technology to Diversify Recombinant Polyclonal Antibody

Symphogen receives milestone payment from Meiji Seika Kaisha

Symphogen to Present Positive Preclinical Data on Sym004 Program for EGF-Receptor Positive Cancers

Biovitrum and Symphogen Report Positive Clinical Results in Novel Rh-immunization Prevention Project

SYMPHOGEN and BIOVITRUM have Initiated a Novel Treatment Study in Autoimmune Bleeding Disorder (ITP)

Symphogen Enters into Strategic Collaboration with Genentech for Antibody Therapeutics in Infectious

Symphogen and Biovitrum Initiate a Second Clinical study with a Novel Treatment of Hemolytic Disease

Biovitrum and Symphogen have Successfully Completed Phase I Clinical Trial